Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
Article 1998 en
Authors
JB
James R. Berenson
AL
Alan Lichtenstein
LP
Lisa A. Porter
Abstract
1 min read
Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy.
James R. Berenson, Alan Lichtenstein, Lester Porter, Meletios A Dimopoulos, Roldolfo Bordoni, Sebastian George, Allan Lipton, Alan Keller, Oscar Ballester, Michael J. Kovacs, Hilary Blacklock, Richard H. Bell, Joseph F. Simeone, Dirk J. Reitsma, Maika Heffernan, John J. Seaman, Robert Knight
Evangelos Terpos, Gareth J. Morgan, Meletios A Dimopoulos, Matthew T. Drake, Suzanne Lentzsch, Noopur Raje, Orhan Sezer, Ramón García‐Sánz, Kazuyuki Shimizu, Ingemar Turesson, Tony Reiman, Artur Jurczyszyn, Giampaolo Merlini, Andrew Spencer, Xavier Leleu, Michèle Cavo, Nikhil C. Munshi, S. Vincent Rajkumar, Brian G.M. Durie, G. David Roodman
Discussion(0)
No comments yet. Be the first to comment.